Panacea Biotec secures $35.65m UNICEF polio vaccine contract

Panacea Biotec Limited has received a letter of award from UNICEF for a long-term agreement to supply bivalent oral polio vaccine (bOPV). The contract, spanning from April 1, 2026, to March 31, 2030, is valued at approximately $35.65 million for Q2 CY2026 and CY2027. The agreement involves the supply of bOPV in both 10 and 20 vial presentations.

This award falls under an international entity, UNICEF, which will publicly disclose details such as the supplier's name, vaccine, award duration, total award value, and awarded prices per supplier per product presentation on its website. The order is not considered a related party transaction.

The supply is for UNICEF's requirements as per orders received periodically. The execution of the initial phase of the order is expected during Q2 CY2026 and CY2027.